ArticleCureus2025
Prediction of Maximum Amplitude With Citrated Rapid Thromboelastography Reaction Time in Cardiac Surgery: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRapid and accurate assessment of coagulation status is essential in cardiac surgery to guide transfusion therapy. The reaction time in citrated rapid thromboelastography (CRT-R) is obtainable within minutes; however, its predictive relationship with maximum amplitude (MA) parameters, particularly platelet- and fibrinogen-related clot strength, remains unclear.
methodsWe retrospectively analyzed TEG6s assays performed in the operating rooms and intensive care units of a single tertiary center from January 2018 to July 2024 in adult patients who underwent cardiac surgery. Pearson coefficients quantified the associations between CRT-R and MA values from the CRT, citrated kaolin with heparinase (CKH), and citrated functional fibrinogen (CFF) assays. Relationships with MA were modeled using an exponential-decay fit, and CRT-R versus TEG-activated clotting time (TEG-ACT) was modeled linearly. Bootstrap resampling (1,000 iterations) estimated CRT-R thresholds corresponding to clinically relevant MA targets (CRT-MA=48 mm; CFF-MA=12 mm).
resultsOf the 2,453 initially identified paired measurements, 104 were excluded (missing values, n=80; CRT-R >5.5 min, n=24), leaving 2,349 paired measurements for analysis. CRT-R showed inverse associations with MA parameters (absolute Pearson r: CFF-MA 0.6224, CRT-MA 0.6215, CKH-MA 0.6022; all p<0.0001) and a weak association with CKH-R (r=0.2897). CRT-R and TEG-ACT were nearly perfectly linear (r=1.000). Bootstrap-derived CRT-R cutoffs were 1.1858 min (95% CI 1.1597-1.2135) for predicting CRT-MA=48 mm and 1.2832 min (95% CI 1.2487-1.3238) for predicting CFF-MA=12 mm. At these thresholds, CRT-R predicted CRT-MA <48 mm with 49.2% sensitivity and 93.8% specificity and predicted CFF-MA <12 mm with 56.9% sensitivity and 97.0% specificity.
conclusionCRT-R, obtainable within minutes of assay initiation, moderately predicts final clot strength, with the strongest link to fibrinogen-dependent CFF-MA. These CRT-R-based thresholds may enable earlier preparation of platelet and fibrinogen therapy within viscoelastic-guided transfusion workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.